Curriculum Vitae (Date Prepared: 1/2026**)**

GEORGE MILLER, MD

Contact

127 Dwight Place
Englewood, NJ 07631
(201) 446-3608

Email: gedalyamil@gmail.com

Education

Year	***Degree***	***Field***	***Institution***
May 1993	BA	Liberal Arts	Columbia College, Columbia University
June 1998	MD CM	Medical School	McGill University Faculty of Medicine

Postdoctoral Training

1998-99	General Surgery Internship	New York University School of Medicine
1999-00	General Surgery Residency	New York University School of Medicine
2000-02	Research Fellowship	Memorial Sloan Kettering Cancer Center
2002-05	General Surgery Residency	New York University School of Medicine
2005-07	Surgical Oncology Fellowship	Memorial Sloan Kettering Cancer Center
2006-07	Hepatobiliary-Pancreatic Fellowship	Memorial Sloan Kettering Cancer Center

Medical Licensure

2001 New York Medical License
2007 New Jersey Medical License
2021 Connecticut Medical License
2023 Florida Medical License

Certification

05/2006	American Board of Surgery
12/2015	American Board of Surgery (Recertification)

Academic Appointments

Year	*Academic Title (Depts of Surgery and Cell Biology)*	*Institution*
2005	Assistant Professor	NYU School of Medicine
2013	Associate Professor	NYU School of Medicine
2015	Associate Professor (Tenure)	NYU School of Medicine
2016	Vice-Chair of Surgery	NYU School of Medicine
2016	H. Leon Pachter Endowed Chair	NYU School of Medicine
2017	Professor (Tenure)	NYU School of Medicine

Employment / Hospital Appointments

Year	*Employer*	*Hospital Title*	*Institution*
2007-2020	NYU	Attending Surgeon	Bellevue Hospital Center, NYU
2009-2020	NYU	Attending Surgeon	NYU Langone Medical Center
2020-2020	NYU	Chairman of Surgery	Woodhull Hospital Center, NYU
2021-2023	Trinity Health of NE	Chief, Surgical Oncology	Trinity Health of NE
2023-Current	Holy Name Med Ctr	Director, Surgical Oncology	Holy Name Medical Center

Awards and Honors

Year	*Name of Award*
2022	Surgical Resident Teaching Award, Trinity Health of New England
2020	TME Study Section – Standing Member
2018	CTSI NYU CTSI Translational Research Mentor of the Year Award
2017	Ruth Leff Siegel Award for Pancreatic Cancer Research
2017	Named Editor in Chief, *Oncogene*
2016	Nominated for University-wide NYU Distinguished Teacher Award
2016	H. Leon Pachter Endowed Chair
2016	NYU Perlmutter Cancer Center Paper of the Year Award
2014	Nominated for Thomas E. Starzl Prize in Surgery and Immunology
2014	AACR-PanCan Award
2013	Elected to American Society for Clinical Investigation
2011	Hirschl Fellowship
2010	Nominated for University-wide NYU Distinguished Teacher Award
2009	Liver Scholar Award, American Liver Foundation
2008	Whitehead Fellowship for Research in Biomedical Sciences (NYU)
2006	Paul & Christina Martin Foundation Fellowship Research Award
2005	Chief Resident Research Award, New York University Department of Surgery
2004	Resident Research Award, New York University Department of Surgery
2004	First Place Award, Top Gun Laparoscopic Skills and Suturing Competition
2004	American Board of Surgery In Service Score Award
2004	Resident Teaching Award, New York University Department of Surgery
2003	Resident Research Award, New York University Department of Surgery (*inaugural award*)
2002	Scholar-in-Training Award, American Association for Cancer Research
2002	Chairman's Award for Research, Memorial Sloan-Kettering (*inaugural award*)
1995	Levitt Foundation Oncology Fellowship, Medical Research Council of Canada
1994	McGill University Faculty of Medicine Research Bursary
1993	Eesti Fellowship, Columbia University
1993	*summa cum laude* (Columbia University)
1992	Phi Beta Kappa (early awardee, Columbia University)
1991	Chandler Undergraduate Research Fellowship (Columbia University)
1989	Empire State Scholarship, New York State Regents Scholarship
1989	Dean's List each semester (Columbia University)
1989	Robert C. Byrd Honors Scholarship (U.S. Senate)

Major Committee Assignments

National

2013	Medical Research Council (UK)
2014	Hepatobiliary Pathophysiology Study Section (NIH)
2014	Medical Research Council (UK)
2015	Chairman, Liver Cancer Study Section, CDMRP (DoD)
2015	Hepatobiliary Pathophysiology Study Section (NIH)
2016	NCI Special Emphasis Panel, Program Project Grant Study Section (NIH)
2017	NCI Tumor Microenvironment Study Section (NIH)
2018	Pancreatic Cancer SPORE EAB, Washington University, St. Louis, MO
2018	Pancreatic Cancer SPORE EAB, Emory University, Atlanta, GA
2018	Pancreatic Cancer SPORE EAB, Columbia University, New York, NY
2019	Pancreatic Care Center EAB, Knight Cancer Institute, OHSU, Portland, OR
2019	NCI Program Project Grant Study Section (NIH)
2020	Standing Member NCI Tumor Microenvironment Study Section (NIH)
2020	New York Academy of Sciences: Systemic Effects of Metastases Organizing Committee
2022	Center for Cancer Immunology and Immunotherapy, EAB, University of Louisville

Local

2011	GI Oncology Chief of Service Search Committee	Member (NYU)
2011	CTSI Pilot Grant Review Committee	Member (NYU)
2011-2015	Tissue Acquisition and Distribution Committee	Member (NYU)
2012-2020	GI Oncology Leadership Group	Co-Leader (NYU)
2015-2020	Cancer Center Executive Committee	Member (NYU)
2015-2020	Tumor immunity & Microenvironment Program	Leader (NYU)
2016	Cancer Center Retreat Planning Committee	Leader (NYU)
2018	Big Gut Seminar: Focus on Complex Liver Diseases	Course Director (NYU)
2019	Big Gut Seminar: Focus on Complex Liver Diseases	Course Director (NYU)
2023	Holy Name Medical Center, Associate Residency Program Director	
2023	Holy Name Medical Center, Cancer Center Executive Committee	
2024	Holy Name Medical Center, Cancer Center Research Committee	
2025	Holy Name Medical Center, OR Committee (Chair)	
2025	Holy Name Medical Center, IRB Committee	

Memberships, Offices, And Committee Assignments In Professional Societies

Year	*Society*
2020	Surgery Biology Club
2017	American Surgical Association
2013	American Society for Clinical Investigation
2013	American Association for the Advancement of Science
2013	International Hepato-Pancreato-Biliary Association
2012	Society of University Surgeons
2012	American Association for the Study of Liver Diseases
2012	American Hepato-Pancreato-Biliary Association

2011 FASEB
2007 American College of Surgeons
2005 Society of Surgical Oncology
2002 American Association for Cancer Research
2001 American Association of Immunologists

Editorial Positions

Editor Emeritus
2026- Oncogene

Editor-in-Chief
2017-2025 Oncogene

Associate Editor
2016 Oncogene

Ad hoc Reviewer
2019-Current Cancer Cell
2018-Current Cancer Discovery
2014-Current Journal of Clinical Investigation
2013-Current Journal of Hepatology
2013-Current Science Translational Medicine
2008-Current Journal of Immunology
2012-Current Hepatology
2010-Current Gastroenterology
2008-Current Inflammation
2008-Current Annals of Surgical Oncology

Major Administrative Responsibilities

2023	System Director of Oncologic Surg.	Holy Name Medical Center
2023	Chief, Surgical Oncology	Holy Name Medical Center
2020	Chair of Surgery	NYU, Woodhull Hospital Center
2015-2020	Director	NYU, Cancer Immunology Program
2014- 2020	Vice-Chair	NYU, Department of Surgery
2012-2018	Co-Leader	NYU, GI Oncology Program

Teaching Experience

Year	Name of course	Type of Teaching	Student contact hours
2015-2020	Molecular Oncology Course	Lecturer	4 hours/year
2011-2020	NIH Cancer Discovery Course	Lecturer	3 hours/year
2007-2020	Surgery Clerkship	Rounds and clinic	250 hours/year
2007-2020	Surgery Seminar	Annual seminar	6 hours/year
2007-2020	Surgery Core Curriculum	Lecturer	6 hours/year

Mentoring of Graduate Students, Residents, Post-Doctoral Fellows in Research

Name	Type of position	Time period	Present position
Primary supervisor			
Junaid Ibrahim	Post-Doc	2008-2010	Faculty (Univ. of Pittsburg)
Ashim Malhotra	Post-Doc	2010-2011	Faculty (Univ. of Pacific)
Adeel Rehman	Post-Doc	2010-2011	Resident (G. Washington U.)
Atsuo Ochi	Post-Doc	2011-2012	Faculty (NYU)
Raghavendra Rao	Post-Doc	2012-2013	Resident (Univ. of Illinois)
Michael Hackman	Post-Doc	2010-2011	Resident (NYU)
Andrea Bedrosian	Resident Research Fellow	2009-2011	Faculty (NYU)
Justin Henning	Resident Research Fellow	2010-2012	Faculty (NYU)
Mohsin Jamal	Post-Doc	2011-2014	Resident (Henry Ford)
Constatin Zambirinis	Post-Doc	2011-2014	Resident (Brown)
Stephanie Greco	Resident Research Fellow	2012-2014	Faculty (Fox Chase)
Michael Deutsch	Resident Research Fellow	2012-2014	Faculty (Penn Sate)
Brittany Rhoades	Graduate student	2012-2013	Pharmaceutical Industry
Lena Tomkoetter	Resident Research Fellow	2013-2014	Faculty (Univ. of Dresden)
Donnele Daley	Resident Research Fellow	2014-2016	Faculty (Univ. of Michigan)
Alejandro Hernandez	Resident Research Fellow	2014-2017	Fellow (U. of Toronto)
Vishnu Mani	Resident Research Fellow	2015-2017	Fellow (Duke)
Mautin Hundeyin	Resident Research Fellow	2015-2018	Fellow (MSKCC)
Brian Diskin	Resident Research Fellow	2016-2019	Resident (NYU)
Joshaua Leinwand	Resident Research Fellow	2017-2020	Resident (Columbia)
Berk Aykut	Resident Research Fellow	2016-2020	
Wei Wang	Post-Doc	2016-2020	
Gregor Werba	Resident Research Fellow	2019-2020	
Thesis Committee			
Jesse Handler	MD/Ph.D Student	2012-2016	MSTP (Bar-Sagi Lab)
Lena Lau	Ph.D Student	2016-Current	PhD (David Gregory)
Daniel McLaughlin	Ph.D Student	2017-Current	PhD (Richard Possemato)

Teaching Awards Received

2018 NYU CTSI Mentor of the year award
2016 NYU Distinguished Teacher Award – Nominee
2010 NYU Distinguished Teacher Award – Nominee
2004 Resident Teaching Award, New York University Department of Surgery

Major Research Interests

1. *Pancreas Inflammation and Oncogenesis* Our lab discovered key cellular and biochemical elements which drive pancreatic inflammation and promote intratumoral immune suppression. On the cellular level, we were the first group to report on the role of dendritic cells in modulating

pancreatic inflammation and inducing immune suppression in the TME by activating pancreatic-antigen restricted Th2 cells. We also described the recruitment of immune suppressive myeloid cells to PDA and their role in vetoing tumoricidal T cell responses and promoting the development of liver metastases. Our recent work has identified γδT cells as critical mediators of immune-suppression in PDA by having superior access to effector $CD4^+$ and $CD8^+$ T cells to mediate checkpoint-based immune-suppression. Our lab also recently found that a unique subset of antigen presenting cells in PDA promote the proliferation of $FoxP3^{neg}$ type I regulatory T cells which generates a unique brand of immune suppression compared with cancers that are more sensitive to immunotherapies. Our lab has elucidated novel biochemical signaling networks which govern peritumoral immune suppression. We showed that TLR7 activation in PDA generates suppressive notch pathway activity in myeloid cells; we showed that TLR9 signaling in peritumoral fibroblasts leads to CCL3 and CCL5 expression which recruits TREGS and MDSC to PDA; we showed that NLRP3 and Dectin-1 engagement in macrophages are central to the tolerogenic M2-like macrophage program which predominates in PDA. My lab was the first characterize a sterile ligand for Dectin-1 by showing that Galectin-9 activates Dectin-1 in PDA leading to suppressive macrophage differentiation. Our lab also was the first to show that organized cellular necrosis, or necroptosis, driven by RIP1 and RIP3 kinases, is commonly induced by chemotherapy and necroptosis paradoxically promotes tumor progression by releasing CXCL1 which recruits MDSC and by activating Mincle, a death receptor in the C-type lectin family. Besides elucidating immune-suppressive networks associated with chemotherapeutics, George's lab has shown that radiation therapy (RT) induces critical immune tolerance which limits its treatment efficacy by directly upregulating M-CSF expression in PDA cells. This leads to massive influx of M2-like macrophages in the 72 hours following RT leading to tolerogenic $CD4^+$ T cell differentiation. Our lab has also published important work on the mediators of cancer-induced cachexia and he has a major paper soon to be published defining the pancreatic cancer microbiome and its overriding immune-suppressive influences. In addition, our findings in the lab are being translated to four separate clinical trials in pancreatic cancer and we are generating new innovative therapeutics based on my basic research.

2. *Innate Immune Signaling in the Liver* Our investigations in liver immunology have been diverse but a unifying theme has been understanding the regulation of acute and chronic liver disease by innate immunity. We showed that both professional (DC) and non-professional (liver endothelial cells) antigen presenting cells are primary orchestrators of fibrosis-promoting inflammation in the diseased liver. In this, we were the first to show that DC can directly induce transdifferentiation of hepatic stellate cells. We also implicated divergent roles for DC in modulating the pathogenesis of NASH and acute liver injury from Acetaminophen. Further, we have done in-depth work in understanding the role of lipids in basic liver DC and macrophage function and their contribution to liver disease. More recently, we have published exciting work on the interface between innate immunity and the biochemical mechanism of hepatocyte cells death after acute liver injury and on the role of innate T cell subsets promoting hepatic regeneration via IL-17.

Research Grant Support

Grant	***Award Date***

National Institutes of Health / R01 CA168611-06 09/01/19
G. Miller (Principal Investigator)
"Targeting RIP1 Kinase in Pancreatic Cancer"
Role: Principal Investigator (multi-PI)
Annual Direct Costs: $230,000

National Institutes of Health / R01 CA215471 01/01/18
G. Miller (Principal Investigator)
"Dectin-1 drives pancreatic cancer by inducing macrophage-mediated immune suppression"
Role: Principal Investigator
Annual Direct Costs: $250,000

National Institutes of Health / R01 CA215471S 06/01/19
G. Miller (Principal Investigator)
"Supplement studying cachexia in pancreatic cancer models"
Role: Principal Investigator
Annual Direct Costs: $250,000

National Institutes of Health / R01 DK106025 08/01/16
G. Miller (Principal Investigator)
"Dectin-1 Regulates Chronic Liver Fibro-inflammatory Disease"
Role: Principal Investigator
Annual Direct Costs: $250,000

National Institutes of Health / R01 CA206105 12/31/21
G. Miller (Principal Investigator)
"Regulation of Pancreatic Oncogenesis by the Gut Microbiome"
Role: Principal Investigator
Annual Direct Costs: $250,000

National Institutes of Health / R41 CA250892 03/30/19
G. Miller (Principal Investigator)
"Modulation of the gut microbiome to enhance efficacy of immunotherapy in PDA"
Role: Principal Investigator
Annual Direct Costs: $200,000

National Institutes of Health / P20 CA252728 10/01/20
J. Ahn (Principal Investigator)
"NYU Cancer Health Disparity SPORE"
Role: Project Leader
Annual Direct Costs: $400,000

National Institutes of Health / P30 CA016087 10/01/20
B. Neel (Principal Investigator)
"Tumor immunology Program"
Role: Project Leader
Annual Direct Costs: $400,000

National Institutes of Health / T32 CA193111-01 06/30/15
G. Miller (Principal Investigator)
"Research Training for Physician-Scientists in Gastrointestinal Oncology"
Role: Principal Investigator
Annual Direct Costs: $300,000

National Institutes of Health / T32 CA193111-06 07/01/20
G. Miller (Principal Investigator)
"Research Training for Physician-Scientists in Gastrointestinal Oncology"
Role: Principal Investigator
Annual Direct Costs: $300,000

National Institutes of Health / R01 DK118971 10/31/18
N. Bunnett (Principal Investigator)
"Trafficking-Dependent Signaling of Pain by Protease-Activated Receptors"
Role: Other Significant Contributor
Annual Direct Costs: $250,000

DoD Idea Award with Special Focus 09/01/18
G. Miller (Principal Investigator)
"Role of Piezo1 signaling in pancreatic carcinoma"
Role: Principal Investigator
Annual Direct Costs: $250,000

Department of Defense Team Science Award 07/01/18
G. Miller (Principal Investigator)
"Targeting the microbiome to enable immunotherapeutic efficacy in PDA"
Annual Direct Costs: $400,000

National Institutes of Health / P20CA252728 10/01/20
J Ahn (Principal Investigator)
"Disparities in gastrointestinal cancers"
Role: Project Leader
Annual Direct Costs: $400,000

Samuel Waxman Foundation Award 06/30/20
G. Miller (Principal Investigator)
"ICOSL signaling programs tumor associated macrophages"
Role: Principal Investigator
Annual Direct Costs: $250,000

Pancreatic Cancer Action Network 09/01/19
G. Miller (Principal Investigator)
"Targeting TIM4 in Pancreatic Carcinoma"
Role: Principal Investigator
Annual Direct Costs: $100,000

V Foundation for Cancer Research - Translational Award 11/01/18
G. Miller (Principal Investigator)
"Targeting RIP1 Kinase in Pancreatic Cancer"
Role: Principal Investigator (multi-PI)
Annual Direct Costs: $200,000

Pfizer Centers for Therapeutic Innovation 12/01/18
G. Miller (Principal Investigator)
"Targeting Piezo1 in Cancer"
Role: Principal Investigator
Annual Direct Costs: $388,000

Pfizer Centers for Therapeutic Innovation 12/01/19
G. Miller (Principal Investigator)
"CRISPR-based screening for immunotherapy sensitizers in pancreatic cancer"
Role: Principal Investigator
Annual Direct Costs: $113,000

NYBO Therapeutics LLC 10/01/18
G. Miller (Principal Investigator)
"Testing of Novel Neutralizing Antibodies for Pancreatic Cancer"
Role: Principal Investigator
Annual Direct Costs: $700,000

GlaxoSmithKline LLC 08/01/18
G. Miller (Principal Investigator)
"ICOS activation in pancreatic carcinoma"
Role: Principal Investigator
Annual Direct Costs: $250,000

Stand up to cancer (SU2C):Pancreatic Cancer Interception Dream Team 12/01/17
*A Kimmelman (*Principal Investigator*)*
"Novel Approaches to Early Pancreatic Cancer"
Role: Co-Investigator
Annual Direct Costs: $2,600,000

Hirschberg Foundation Seed Grant 12/01/19
G. Miller (Principal Investigator)
"Targeting microbiome to enable efficacy for immunotherapy in PDA"
Role: Mentor
Annual Direct Costs: $40,000

American Hepato-Pancreato-Biliary Association 07/01/19
J Leinwand (Principal Investigator)
"Role of microbiome in hepatic inflammation"
Role: Mentor
Annual Direct Costs: $30,000

NIH F30 Training Grant 07/01/19
E. Kurz (Principal Investigator)
"ICOSL signaling in myeloid cells (need exact title)"
Role: Mentor
Annual Direct Costs: $~100,000

Clinical & Translational Science Institute TL1 Pre-doc. Training Grant 07/01/18
E. Kurz (Principal Investigator)
"The Role of RIP1 on Programming of Immune Tolerance in the Pancreatic Cancer"
Role: Mentor
Annual Direct Costs: $40,000

American College of Surgeons Resident Research Scholarship 07/01/18
B. Diskin (Principal Investigator)
"The Role of Galectin-9 in Pancreatic Ductal Adenocarcinoma"
Role: Mentor
Annual Direct Costs: $30,000

National Institutes of Health / R01 CA168611 04/01/13
G. Miller (Principal Investigator)
"Toll-like Receptor Regulation of Pancreatic tumorigenesis"
Role: Principal Investigator
Annual Direct Costs: $250,000

National Institutes of Health / R01 CA215471-S1 09/18/18
G. Miller (Principal Investigator)
"Dectin-1 drives pancreatic cancer by inducing macrophage-mediated immune suppression"
Role: Principal Investigator
Annual Direct Costs: $250,000

National Institutes of Health / R01 CA164964 09/01/14
J. Ahn (Principal Investigator)
"Prospective Study of Oral Microbiome with Pancreatic Cancer"
Role: Co-Investigator
Annual Direct Costs: $250,000

National Institutes of Health / R03 DK098303 02/15/13
G. Miller (Principal Investigator)
"Effect of dendritic cell lipid content on hepatic inflammation and NASH pathogenesis"

Role: Principal Investigator
Annual Direct Costs: $50,000

National Institutes of Health / K08 DK085278 05S1 01/01/15
G. Miller (Principal Investigator)
"Role of dendritic cells in the pathogenesis of liver fibrosis"
Role: Principal Investigator
Annual Direct Costs: $150,000

National Institutes of Health / K08 DK085278 01/01/10
G. Miller (Principal Investigator)
"Role of dendritic cells in the pathogenesis of liver fibrosis"
Role: Principal Investigator
Annual Direct Costs: $150,000

GlaxoSmithKline LLC 08/01/18
G. Miller (Principal Investigator)
"Testing of human RIPK1 inhibitor in 3D models and combination therapies"
Role: Principal Investigator
Annual Direct Costs: ~$250,000

NYBO Therapeutics LLC 05/01/17
G. Miller (Principal Investigator)
"Generation of Novel Neutralizing Antibodies for Pancreatic Cancer"
Role: Principal Investigator
Annual Direct Costs: $500,000

National Institutes of Health / R24 OD18340 03/01/14
David Levy (Principal Investigator)
"Restoring Biospecimen Research Resources Lost Due to Super Storm Sandy"
Role: Project Leader (Co-PI)
Annual Direct Costs: $4,000,000

German Research Foundation (Federal Career Development Award) 07/01/16
B. Aykut (Principal Investigator)
"The Role of γδ T Cells in Pancreatic Tumorigenesis"
Role: Mentor
Annual Direct Costs: $75,000

Pancreatic Cancer Action Network-AACR Translational Research Grant 07/01/17
G. Miller (Principal Investigator)
"Targeting Gamma Delta T-Cells in Pancreatic Carcinoma"
Role: Principal Investigator
Annual Direct Costs: $100,000
This grant was declined because of overlap

GlaxoSmithKline LLC 10/01/17
G. Miller (Principal Investigator)
"ICOS signaling in pancreatic cancer"
Role: Principal Investigator
Annual Direct Costs: $450,000

GlaxoSmithKline LLC 05/24/17
G. Miller (Principal Investigator)
"RIP1 inhibition in cancer"
Role: Principal Investigator
Annual Direct Costs: $137,000

American Cancer Society Postdoctoral Research Fellowship 02/01/18
L. Chen (Principal Investigator) "Targeting galectin-9 in pancreatic cancer"
Role: Co-Mentor
Annual Direct Costs: $50,000

Lustgarten Foundation Grant 01/01/13
G. Miller (Principal Investigator)
"Role of the intestinal microbiome in promoting pancreatic carcinogenesis"
Role: Principal Investigator
Annual Direct Costs: $250,000

American Liver Foundation Postdoctoral Research Fellowship 07/01/17
W. Wang (Principal Investigator)
"Role of gamma delta-T cells in the pathogenesis of NASH"
Role: Mentor
Annual Direct Costs: $12,000

National Institutes of Health / R21 CA155649 01/01/11
G. Miller (Principal Investigator)
"Role of dendritic cells in pancreatic tumorigenesis"
Role: Principal Investigator
Annual Direct Costs: $150,000

DoD - Peer Reviewed Medical Research Program (PRMRP) 09/01/12
G. Miller (Principal Investigator)
"Divergent Effects of Dendritic Cells on Pancreatitis"
Role: Principal Investigator
Annual Direct Costs: $250,000

Pancreatic Cancer Action Network-AACR Innovative Grant 07/01/14
G. Miller (Principal Investigator)
"Regulation of Pancreatic Tumorigenesis by Necroptosis"
Role: Principal Investigator
Annual Direct Costs: $100,000

CTSI Training Program in Clinical and Translational Research 07/01/16
A. Torres-Hernandez (Principal Investigator)
"Syk regulation of liver fibrosis"
Role: Mentor
Annual Direct Costs: $50,000

Society of Surgical Oncology Clinical Investigator Award 04/01/15
G. Miller (Principal Investigator)
"Modulation of tumor-promoting influences of γδT cells in pancreatic carcinoma in a Phase II clinical trial utilizing perioperative gemcitabine + nab-paclitaxel"
Role: Principal Investigator
Annual Direct Costs: $50,000

Hirshberg Foundation for Pancreatic Cancer Research Seed Grant 11/01/15
G. Miller (Principal Investigator)
*"*γδT Cell Mediated Immune Suppression in Pancreatic Oncogenesis"
Role: Principal Investigator
Annual Direct Costs: $50,000

Cancer Center Developmental Prog. Project (NCI P30CA016087) 09/01/15
G. Miller (Principal Investigator)
"Modulation of tumor-promoting influences of γδT cells in a Phase Ib clinical trial utilizing novel immunotherapy regimens for advanced pancreatic carcinoma"
Role: Principal Investigator
Annual Direct Costs: $50,000

NYU Office of Therapeutic Alliances 11/01/15
G. Miller (Principal Investigator)
*"*Depletion of γδ T cells in Invasive Murine Pancreatic Ductal Adenocarcinoma"
Role: Principal Investigator
Annual Direct Costs: $27,000

German Research Foundation (Federal Career Development Award) 09/01/14
L Tomkoetter (Principal Investigator)
"The role of γδ T cells in pancreatic tumorigenesis"
Role: Mentor
Annual Direct Costs: $75,000

Schwartz Research Fellowship in GI Oncology 07/01/14
D Daley (Principal Investigator)
"The Role of Necroptosis in the Development and Progression of Pancreatic Cancer"
Role: Mentor
Annual Direct Costs: $100,000

NYU Physician-Scientist Training Program 07/01/15

A. Torres-Hernandez (Principal Investigator)
"Syk signaling in liver fibrosis"
Role: Mentor
Annual Direct Costs: $50,000

American Liver Foundation Postdoctoral Fellowship Award 07/01/15
A. Torres-Hernandez (Principal Investigator)
"Role of GM-CSF in liver fibrosis"
Role: Mentor
Annual Direct Costs: $12,500

Society of University Surgeons Resident Research Award 05/01/15
A. Torres-Hernandez (Principal Investigator)
"Role of GM-CSF in liver fibrosis"
Role: Mentor
Annual Direct Costs: $30,000

American Society of Colon and Rectal Surgery Research Grant 10/01/15
Mautin Hundeyin (Principal Investigator)
"Role of Dectin-1 in Ulcerative colitis and colon cancer"
Role: Mentor
Annual Direct Costs: $20,000

NYU Office of Therapeutic Alliances 4/01/16
G. Miller (Principal Investigator)
"Galectin-9 neutralization in invasive murine pancreatic ductal adenocarcinoma"
Role: Principal Investigator
Annual Direct Costs: $31,000

Incentive Award - NYU Office of Science and Research 4/01/16
G. Miller (Principal Investigator)
"Gamma Delta T Cell Mediated Immune Suppression in Pancreatic Oncogenesis"
Role: Principal Investigator
Annual Direct Costs: $70,000

Society of University Surgeons Junior Faculty Award 07/01/10
G. Miller (Principal Investigator)
"Intra-hepatic immune supression from gastrointestinal tumors enable liver metastases"
Role: Principal Investigator
Annual Direct Costs: $30,000

Pancreatic Cancer Action Network-AACR Research Acceleration Grant 07/01/13
R. Vonderheide (Principal Investigator)
"Accelerating development of CD40 therapy for pancreatic cancer"
Role: Co-Investigator
Annual Direct Costs: $100,000

Hirschl Weill-Caulier Research Award 01/01/11
G. Miller (Principal Investigator)
"Dendritic cells link chronic pancreatitis to pancreatic carcinoma"
Role: Principal Investigator
Annual Direct Costs: $30,000

National Pancreas Foundation Grant 07/01/11
G Miller (Principal Investigator)
"Role Toll like receptor ligation in pancreatic carcinogenesis"
Role: Principal Investigator
Annual Direct Costs: $50,000

National Pancreas Foundation Grant 07/01/13
C Zambirinis (Principal Investigator)
"The role of bacteria in modulating pancreatic tumorigenesis"
Role: Mentor
Annual Direct Costs: $50,000

American Liver Foundation Postdoctoral Fellowship Award 07/01/13
M Deutsch (Principal Investigator)
"Role of C-type Lectin receptors dectin and mincle in Con-A hepatitis"
Role: Mentor
Annual Direct Costs: $12,500

American Hepato-Pancreato-Biliary Association 07/01/13
S Greco (Principal Investigator)
"Regulation of acute pancreatitis by C-type lectin receptors"
Role: Mentor
Annual Direct Costs: $30,000

NYU Cancer Institute Collaborative Pilot Project Award 10/01/12
G. Miller (Principal Investigator)
"Role of intestinal microbiome in pancreatic carcinogenesis"
Role: Principal Investigator
Annual Direct Costs: $25,000

NYU School of Medicine - Program Project Development Award 07/1/11
G. Miller (Principal Investigator)
"Cross-communications between stroma and epithelium in pancreatic cancer initiation and progression"
Role: Dual Principal Investigator
Annual Direct Costs: $100,000

NYU Physician-Scientist Training Program 07/01/10
J Henning (Principal Investigator)

"Role of dendritic cells in the pathogenesis of NASH"
Role: Mentor
Annual Direct Costs: $45,000

American Liver Foundation Postdoctoral Fellowship Award 07/01/14
L Tomkoetter (Principal Investigator)
"Role of Dectin-1 in liver fibrosis"
Role: Mentor
Annual Direct Costs: $12,500

National Pancreas Foundation Grant 07/01/10
A Malhotra (Principal Investigator)
"Role of dendritic cells in pancreatic carcinogenesis"
Role of tumor infiltrating DC in pancreatic dysplasia and stellate cells activation.
Role: Mentor
Annual Direct Costs: $50,000

Liver Scholar Award - American Liver Foundation 07/01/09
G. Miller (Principal Investigator)
"Dendritc cell activation during liver injury and their contribution to hepatic cirrhosis"
Role: Principal Investigator
Annual Direct Costs: $50,000

National Institutes of Health CTSI Pilot Grant / 1UL1RR029893 02/15/10
S. Cohen (Principal Investigator)
"Clinical and experimental significance of CCL chemokines in acute pancreatitis"
Role: Co-Principal Investigator
Annual Direct Costs: $25,000

Ralph S. French Charitable Foundation 05/01/14
G. Miller (Principal Investigator)
"Purchase of Mouse Ultrasound Machine for GI Cancer Research"
Role: Principal Investigator
Annual Direct Costs: $300,000

Whitehead Fellowship for Junior Faculty 09/01/08
G. Miller (Principal Investigator)
"Role of resident hepatic myeloid derived suppressor cells in enabling hepatic metastases from GI cancers"
Role: Principal Investigator
Annual Direct Costs: $10,000

Paul & Christina Martin Gallbladder Cancer Foundation Award 07/01/06
G. Miller (Principal Investigator)
"Genomic analysis of cancers of the gallbladder and bile ducts"
Role: Principal Investigator

Annual Direct Costs: $50,000

Levitt Grant in Oncology, Medical Research Council of Canada 07/01/95
G. Miller (Principal Investigator)
"Role of amyloid beta expression in lymphoid cells"
Role: Principal Investigator
Annual Direct Costs: $5,000

Peer Reviewed Publications

1. **G Miller**, J Boman , I Shrier, PH Gordon. Natural history of patients with adhesive small bowel obstruction. *British Journal of Surgery* 2000, 87(9):1240-7

2. **G Miller**, J Boman, I Shrier, PH Gordon. Etiology of small bowel obstruction. *American Journal of Surgery* 2000, 180(1):33-6

3. **G Miller**, J Boman, I Shrier, PH Gordon. Small-bowel obstruction secondary to malignant disease: an 11-year audit. *Canadian Journal of Surgery*, 2000 43(5):353-8

4. **G Miller**, S Lahrs, RP DeMatteo. Adenoviral-mediated interleukin-12 gene transfer activates dendritic cells and enhances their anti-tumor immunity. *Surgical Forum* 2001, 52:241-42

5. **G Miller**, S Lahrs, VG Pillarisetty, AB Shah, RP DeMatteo. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T cell mediated tumor protection. *Cancer Research* 2002, 62(18):5260-6

6. **G Miller**, VG Pillarisetty, AB Shah, S Lahrs, RP DeMatteo. Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. *Journal of Immunology* 2002, 169(6):2875-85

7. **G Miller**, J Boman, I Shrier, PH Gordon. Readmission for small-bowel obstruction in the early postoperative period: etiology and outcome. *Canadian Journal of Surgery* 2002, 45(4):255-58.

8. Fraser SA, I Shrier, **G Miller**, PH Gordon. Immediate postlaparotomy small bowel obstruction: a 16-year retrospective analysis. *American Surgeon* 2002, 68(9):780-82

9. **G Miller**, S Lahrs, RP DeMatteo. Overexpression of interleukin-12 enables dendritic cells to activate natural killer cells and confer systemic anti-tumor immunity. *FASEB Journal* 2003 17(4):728-30

10. **G Miller**, S Lahrs, VG Pillarisetty, AB. Shah, RP DeMatteo. Murine flt-3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. *Journal of Immunology* 2003, 170(7):3554-64

11. **G Miller**, S Lahrs, AB Shah, RP DeMatteo. Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus. *Cancer Immunology and Immunotherapy* 2003, 52(6):347-58

12. VG Pillarisetty, **G Miller,** AB Shah, RP DeMatteo. Granulocyte-macrophage colony-stimulating factor expands dendritic cells and their progenitors in mouse liver. *Hepatology* 2003, 37(3):641-52

13. D Boffa, B Feng, V Sharma, RP DeMatteo, **G Miller**, M Suthanthiran, R Nunez, HC Liou. The selective loss of c-Rel compromises dendritic cell activation of T lymphocytes. *Cellular Immunology* 2003, 222(2):105-15

14. **G Miller**, VG Pillarisetty, AB Shah, S Lahrs, RP DeMatteo. Natural killer cell depletion misprepresents the mechanism of tumor protection after Interleukin-12 gene transfer to hepatocytes. *International Journal of Cancer* 2004, 110(3):395-402

15. VG Pillarisetty, AB Shah**, G Miller**, Joshua I Bleier, RP DeMatteo. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. *Journal of Immunology* 2004, 172(2):1009-17

16. **G Miller**, ZM Bamboat, F Allen, MA Hopkins, TH Gouge, TS Riles, MM Nalbandian. Attitudes of applicants for surgical residency toward work hour limitations. *American Journal of Surgery* 2004, 188(2):131-5.

17. **G Miller**. Potential impact of the 80-hour work week on interest in surgery as a career. *Focus on Surgical Education* 2004, 21(3):16-17

18. **G Miller**, ZM Bamboat, F Allen, P Biernacki, MA Hopkins, TH Gouge, TS Riles. Impact of mandatory resident work hour limitations on medical students' interest in surgery. *Journal of the American College of Surgeons* 2004, 199(4):613-17

19. AA MacLean, **G Miller**, ZM Bamboat, K Hiotis. Abdominal wall necrotizing fasciitis from dislodged percutaneous endoscopic gastrostomy tubes: a case series. *American Surgeon* 2004, 70(9):827-31

20. **G Miller**, D Yim, M Macari, M Harris, P Shamamian. Retroperitoneal perforation of the duodenum from biliary stent erosion. *Current Surgery* 2005, 62(5):512-15

21. **G Miller**, C Mueller, D Yim, H Liang, S Marcus, M Macari, P Shamamian. Perforated duodenal diverticulitis: a case series. *Digestive Surgery*, 2005, 22(3):198-202

22. **G Miller,** L Schwartz, M D'Angelica. The use of imaging in the diagnosis and staging of hepatobiliary cancers. *Surgical Oncology Clinics of North America*, 2007, 16(2):343-368

23. **G Miller**, P Biernacki, EA Minnard, N Kemeny, RL Sun, M Burt, R Downey, WR. Jarnagin, M D'Angelica, L H Blumgart, Y Fong, RP DeMatteo. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. *Journal of the American College of Surgeons*, 2007, 205(2):231-8.

24. J Wolf, **G Miller**, R Ashinoff, J Dave, RS Lefleur, S Frangos, M Miglietta. Pancreatic ureteral fistula following penetrating abdominal trauma. *Journal of the Pancreas*, 2007, 8(5):613-6.

25. **G Miller**, WR Jarnagin. Gallbladder carcinoma. *European Journal of Surgical Oncology*, 2007, 34(3):306-12.

26. J Wolf, **G Miller**, R Sultan, M Miglietta, S Frangos. Hypopharyngeal rupture associated with Hangman's fracture after blunt trauma. *Surgical Rounds*, 2007, 12:571-73.

27. **G Miller**, AA MacLean, K Hiotis. Necrotizing fasciitis of the abdominal wall. *Canadian Journal of Surgery* 2008, 51(1):56.

28. **G Miller**, ND Socci, D Dhall, M D'Angelica, RP DeMatteo, PJ Allen, B Singh, Y Fong, LH Blumgart, DS Klimstra, WR Jarnagin.Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. *Journal of Experimental and Clinical Cancer Research*. 2009, 28:62-70

29. M Connolly, A Bedrosian, J Mallen-St-Clair, J Ibrahim, HL Pachter, D Bar-Sagi, A Frey, **G Miller.** In hepatic fibrosis, liver dendritic cells govern hepatic inflammation in mice via TNF-α. *Journal of Clinical Investigation*. 2009, 119(11):3213-25

30. M Connolly, J Mallen-St-Clair, A Bedrosian, J Ibrahim, HL Pachter, D Bar-Sagi, A Frey, **G Miller.** Tumor enabling myeloid-derived suppressor cells accumulate in the liver of tumor bearing hosts. *Journal of Leukocyte Biology*. 2010, 87(4):713-25

31. MK Connolly, AS Bedrosian, A Malhotra, JR Henning, J Ibrahim J, V Vera, NE Cieza-Rubio, BU Hassan, HL Pachter, Cohen S, Frey AB, **G Miller.** In hepatic fibrosis, liver sinusoidal endothelial cells gain enhanced immunogenicity. *Journal of Immunology*. 2010, 185(4):2200-8.

32. LG Wich, M Ma, RS Berman, AC. Pavlick, RL Shapiro, **G Miller**, U Sarpel, LS Price, JD Goldberg, I Osman, Impact of socioeconomic status on melanoma presentation and treatment among non-white melanoma patients**.** *Journal of Community Health*. 2011, 36(3):461-8.

33. MK Connolly, D Ayo, A Malhotra, M Hackman, AS Bedrosian, A Nguyen, JR Henning, J Ibrahim, NE Cieza-Rubio, M Dorvil, HL Pachter, **G Miller**. Dendritic cells protect against acetaminophen induced hepatotoxicity. *Hepatology.* 2011, 54(3):959-68.

34. AS Bedrosian, A Nguyen, M Hackman, A Malhotra, JR Henning, J Ibrahim, NE Cieza-Rubio, S Cohen, HL Pachter, AB Frey, **G Miller**. Dendritic cells promote pancreas viability in mice with acute pancreatitis. *Gastroenterology*. 2011, 141(5):1915-26.

35. M Melis, F Marcon, A Masi, U Sarpel, **G Miller**, H Moore, S Cohen, R Berman, HL Pachter, E Newman. Effect of intra-operative fluid volume on peri-operative outcomes after pancreaticoduodenectomy for pancreatic adenocarcinoma. *Journal of Surgical Oncology* 2012, 105(1):81-4.

36. M Marr, K Hemmert, AH. Nguyen, R Combs, A Annamalai, **G Miller**, HL Pachter, J Turner, K Rifkind, and SM Cohen. Team Play in Surgical Education: A Simulation-Based Study, *Journal of Surgical Education* 2012, 69(1):63-9.

37. J Mallen-St.Clair, R Soydaner-Azeloglu, KE Lee, L Taylor, A Livanos, Y Pylayeva-Gupta, **G Miller**, R Margueron, D Reinberg, D Bar-Sagi. EZH2 couples pancreatic regeneration to neoplastic progression. *Genes & Development*. 2012, 26(5);439-44.

38. J Ibrahim, AH Nguyen, A Rehman, A Ochi, M Jamal, CS Graffeo, JR Henning, CP Zambirinis, N Fallon, R Barilla, S Badar, A Mitchell, R Rao, D Acehan, AB Frey**, G Miller**. Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver. *Gastroenterology*. 2012, 143(4):1061-72.

39. Y Pylayeva-Gupta, C Hajdu, **G Miller**, D Bar-Sagi. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. *Cancer Cell.* 2012, 21(6);836-847.

40. M Melis, F Marcon, A Masi, A Pinna, U Sarpel, **G Miller**, H Moore, S Cohen, R Berman, HL Pachter, E Newman. The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits. *HPB* 2012, 14(9):583-588.

41. A Ochi, AH Nguyen, AS. Bedrosian, HM Mushlin, S Zarbakhsh, R Barilla, C Zambirinis, N Fallon, A Rehman, Y Pylayeva-Gupta, S Bader, C Hajdu, AB Frey, D Bar-Sagi, **G Miller**. MyD88 inhibition augments dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. *Journal of Experimental Medicine.* 2012, 209(9):1671-87.

42. A Ochi, CS Graffeo, CP Zambirinis, A Rehman, M Hackman, N Fallon, JR. Henning, RM Barilla, M Jamal, R Rao, S Greco, M Deutsch, Usama Bin Saeed, CH Hajdu, **G Miller**. Toll-Like Receptor 7 Regulates Pancreatic Carcinogenesis. *Journal of Clinical Investigation*. 2012, 122(11):4118–4129.

43. CP Zambirinis, **G Miller**. Signaling via MyD88 in the pancreatic tumor microenvironment: A double-edged sword. *Oncoimmunology* 2013, 2(1):e22567.

44. CP Zambirinis, A Ochi, S Greco, M Deutsch, RM Barilla, **G Miller**. Cell cycle perturbations after Toll-like Receptor 7 activation in pancreatic cancer. *Cell Cycle* 2013, 12(8):1153-1154.

45. A Rehman, KC. Hemmert, A Ochi, JP Quesada, M Ego-Osuala, JR Henning, C Zambirinis, R Barilla, R Rao, S Badar, S Greco, M Deutsch, S Narayan, S Kumar, CS Graffeo, **G Miller**. Role of Fatty Acid Synthesis in Dendritic Cell Generation and Function. *Journal of Immunology* 2013, 190(9):4640-9.

46. JR Henning, CS Graffeo, A Rehman, N Fallon, C Zambirinis, A Ochi, R Barilla, M Jamal, M Deutsch, S Greco, M Ego-Osuala, U Bin Saeed, R Rao, S Badar, JP Quesada, D Acehan, **G Miller**. Dendritic Cells Limit Fibro-Inflammatory Injury in NASH. *Hepatology* 2013, 58(2):589-602.

47. H Court, M Hackman, **G Miller**, KE Lee, D Bar-Sagi, M Bergo, M Philips. Icmt Deficiency Accelerates the Progression of a K-Ras-driven Mouse Model of Pancreatic Ductal Adenocarcinoma. *Journal of Clinical Investigation* 2013;123(11):4681–4694.

48. B Ramkhelawon, EJ Hennessy, M Ménager, FJ Sheedy, TD Ray, A Wanschel, S Babunovic, S Oldebeken, M Geoffrion, W Spiro, **G Miller**, R McPherson, DR Littman, KJ Rayner, KJ Moore. Netrin-1 promotes adipose tissue macrophage retention and insulin resistance in obesity. *Nature Medicine* 2014;20(4):377-84.

49. M Rielland, DJ Cantor, R Graveline, C Hajdu, L Mara, B Diaz, **G Miller**, G David. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression *Journal of Clinical Investigation*. 2014;124(5):2125-35.

50. N Seetharamu, J Melamed, **G Miller**, H Rotterdam, T Gonda, G Villanueva, B Halmos. Complete Pathological Response in a Patient with Metastatic Esophageal Cancer Treated with a Regimen of Capecitabine, Oxaliplatin and Docetaxel: A Case Report. *Journal of Gastrointestinal Cancer* 2014; 45:108-11.

51. C Zambirinis, S Pushalkar, D Saxena, **G Miller**. Role of the intestinal microbiome in pancreatic cancer. *The Cancer Journal* 2014;20(3):195-202.

52. R Rao, CS Graffeo, R Gulati, M Jamal, S Narayan, C Zambirinis, R Barilla, M Deutsch, S Greco, A Ochi, L Tomkötter, R Blobstein, A Avanzi, DM Tippens, Y Gelbstein, E Van Heerden, **G Miller**. Interleukin 17-Producing γδT Cells Promote Hepatic Regeneration in Mice. *Gastroenterology* 2014; 147(2):473-484.

53. JJ Kamphorst, M Nofal, C Commisso, S Hackett, W Lu, E Grabocka, MG Vander Heiden, **G Miller**, JA Drebin, D Bar-Sagi, CB Thompson, JD Rabinowitz. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. *Cancer Research* 2015; 75(3):544-53.

54. M Deutsch, CS Graffeo, R Rokosh, M Pansari, A Ochi, EM Levie, DM Tippens, S Greco, R Barilla, L Tomkötter, CP Zambirinis, A Avanzi, R Gulati, HL Pachter, A Torres-Hernandez, D Daley, **G Miller**. Divergent effects of RIP1 or RIP3 blockade in murine

models of acute liver injury. *Cell Death and Disease* 2015; doi: 10.1038/cddis.2015.126.

55. S Greco, L Tomkötter, AK Vahle, R Rokosh, A Avanzi, SK Mahmood, M Deutsch, S Alothman, D Alqunaibit, A Ochi, CP Zambirinis, T Mohaimin, M Rendon, EM Levie, M Pansari, A Torres-Hernandez, D Daley, R Barilla, HL Pachter, DM Tippens, H Malik, A Boutajangout, T Wisniewski, **G Miller**. TGF-β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia. *Plos One* 2015; 10(7): e0132786. doi:10.1371/journal.pone.0132786.

56. NK Narayanan, K Kunimasa, Y Yamori, M Mori, H Mori, K Nakamura, **G Miller**, U Manne, AK Tiwari, B Narayanan. Antitumor activity of melinjo (Gnetum gnemon L) seed extract in human and murine tumor models in vitro and in a colon-26 tumor-bearing mouse model in vivo. *Cancer Medicine* 2015; 4(11):1767-80.

57. CP Zambirinis, E Levie, S Nguy, A Avanzi, R Barilla, Y Xu, L Siefert, D Daley, S Greco, M Deutsch, S Jonnadula, A Torres-Hernandez , D Tippens, S Pushalkar, A Eisenthal, D Saxena, J Ahn, C Hajdu, DD Engle, D Tuveson, **G Miller**. TLR9 Ligation in Pancreatic Stellate Cells Promotes Tumorigenesis. *Journal of Experimental Medicine*. 2015;212(12):2077-94.

58. L Seifert, M Deutsch, S Alothman, D Alqunaibit, G Werba, M Pansari, M Pergamo, A Ochi, A Torres-Hernandez, E Levie, D Tippens, S Greco, S Tiwari, NN Giao Ly, A Eisenthal, E van Heerden, A Avanzi, R Barilla, C Zambirinis, M Rendon, D Daley, HL Pachter, C Hajdu, **G Miller**. Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways. *Cell Reports*. 2015;(9): 1909-1921.

59. SH Greco, SK Mahmood , AK Vahle, A Ochi, J Batel, M Deutsch, R Barilla, L Seifert, HL Pachter, D Daley, A Torres-Hernandez, M Hundeyin, VR Mani, **G Miller**. Mincle suppresses Toll-like receptor 4 activation. *Journal of Leucocyte Biology*. 2016; 100(1):185-94.

60. L Seifert, G Werba, S Tiwari, NNG Ly, S Nguy, S Alothman, D Alqunaibit, A Avanzi, D Daley, R Barilla, D Tippens, A Torres-Hernandez, M Hundeyin, V Mani, C Hajdu, I Pellicciotta, P Oh, K Du, **G Miller**. Radiation Therapy Induces Macrophages to Suppress Immune Responses Against Pancreatic Tumors in Mice. *Gastroenterology*. 2016; 50(7):1659-1672.

61. L Seifert, G Werba, S Tiwari, NNG Ly, S Alothman, D Alqunaibit, A Avanzi, R Barilla, D Daley, SH Greco, A Torres-Hernandez, M Pergamo, A Ochi, CP Zambirinis, M Pansari, M Rendon, D Tippens, M Hundeyin, VR Mani, C Hajdu, D Engle, **G Miller**. The Necrosome Promotes Pancreas Oncogenesis via CXCL1 and Mincle Induced Immune Suppression. *Nature*. 2016; 532(7598):245-9.

62. R Caso, **G Miller**. Role of tumor associated macrophages in regulating pancreatic cancer progression. *World Journal of Immunology*. 2016; 6(1): 9-18.

63. M Thorn, P Guha, M Cunetta, NJ Espat, **G Miller**, RP Junghans, SC Katz. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. *Cancer Gene Therapy*. 2016; 23(6):188-198.

64. G Werba, L Seifert, **G Miller**. Necroptotic Cell Death – An Unexpected Driver of Pancreatic Oncogenesis. *Cell Cycle*. 2016; 15(16):2095-2096.

65. D Daley, CP Zambirinis, Lena Seifert, N Akkad, N Mohan, G Werba, RM. Barilla, A Torres-Hernandez, M Hundeyin, V Mani, A Avanzi, D Tippens, R Narayanan, Jung-Eun Jang, E Newman, VG Pillarisetty, ML Dustin, D Bar-Sagi, , C Hajdu**, G Miller**. γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation. *Cell*. 2016, 166(6): 1485-1499.

66. SH Greco, A Torres-Hernandez, A Kalabin, C Whiteman, R Rokosh, S Ravirala, A Ochi, J Gutierrez, MA Salyana, VR. Mani, SV Nagaraj, L Seifert, D Daley, M Hundeyin, Yuriy Nikifrov, SC Katz, **G Miller**. Mincle Signaling Promotes Con-A Hepatitis. *Journal of Immunology*. 2016, 197(7):2816-27.

67. L Seifert, **G Miller**. Molecular Pathways: The Necrosome and its Synergistic Interplay with Chemo- and Immunotherapies in Pancreatic Carcinoma. *Clinical Cancer Research*. 2016; 23(5); 1132-1136.

68. Torres-Hernandez A, **Miller G**. TIMPing Fate: Why Pancreatic Cancer Cells Sojourn in the Liver**.** *Gastroenterology*. 2016. S0016-5085(16)35132.

69. Pergamo M, **Miller G**. Myeloid Derived Suppressor Cells and their Role in Pancreatic Cancer. *Cancer Gene Therapy*. 2017; 24, 100-105.

70. Daley D, **Miller G**. The Role of Gamma Delta T cells in Pancreatic Cancer: what could this mean for the clinic? *Expert Review of Gastroenterology and Hematology*. 2017; 11(7); 609-610.

71. Zambrinis C, **Miller G**. Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. *Trends in Molecular Medicine*. 2017; 23 (5); 465-481.

72. X Fan, AV Alekseyenko, J Wu, BA Peters, EJ Jacobs, SM Gapstur, MP Purdue, CC Abnet, R Stolzenberg-Solomon, **G Miller**, J Ravel, RB Hayes, J Ahn. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. *Gut*. 2016 doi: 10.1136/gutjnl-2016-312580. [Epub ahead of print]

73. BA Peters, C Dominianni JA Shapiro, TR Church, J Wu, **G Miller**, E Yuen; H Freiman, I Lustbader, J Salik, C Friedlander, RB Hayes, J Ahn. The Gut Microbiota in Conventional and Serrated Precursors of Colorectal Cancer. *Microbiome* 2016; 4(1):69.

74. D Daley, VR Mani, N Mohan, N Akkad, A Ochi, KB Lee, DW Heindel, CP Zambirinis, G Werba, RM Barilla, A Torres-Hernandez, S Nayak, D Wang, M Hundeyin, B Diskin, B

Aykut, R Rodriguez, S Chang, L Gardner, LK Mahal, B Ueberheide, **G Miller**. Dectin-1 Signaling Drives Pancreatic Oncogenesis by Promoting Adaptive Immune Suppression. *Nature Medicine*. 2017; 23; 556-567

75. D Daley, VR Mani, N Mohan, N Akkad, KB Lee, A Torres-Hernandez, B Aykut, B Diskin, K Ismail, A Mahmud, G Werba, E Morales, S Lall, M Farooq, B Wadowski, A Rubin, M Berman, R Narayanan, M Hundeyin, **G Miller**. NLRP3 Signaling Drives Macrophage Induced Adaptive Immune Suppression in Pancreatic Carcinoma. *Journal of Experimental Medicine*. 2017; 214 (6): 1711-1724.

76. Jang JE, Hajdu CH, Liot C, **Miller G**, Dustin ML, Bar-Sagi, D. Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. *Cell Reports*. 2017; 20(3):558-571.

77. S Guo, M Contratto, **G Miller**, L Leichman, and Jennifer Wu. Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. *World Journal of Clinical Oncology*. 2017; 8(3):230-240.

78. S Pushalkar, M Hundeyin, D Daley, CP Zambirinis, E Kurz, A Mishra, N Mohan, B Aykut, M Usyk, LE Torres, G Werba, K Zhang, Y Guo, Q Li, N Akkad, S Lall, B Wadowski, J Gutierrez, JA Kochen Rossi, JW Herzog, B Diskin, A Torres-Hernandez, J Leinwand, W Wang, PS Taunk, S Savadkar, M Janal, X Li, D Cohen, RB Sartor, D Saxena, **G Miller**. A Distinct Gut Microbiome Promotes Pancreatic Oncogenesis by Induction of Innate and Adaptive Immune Suppression. *Cancer Discovery*. 2018; 8(4):403-416.

79. **G Miller**, J Stebbing. Thirty years of oncogene. *Oncogene*. 2018; 37(5):553-554.

80. S Katz, P Guha, J Gardell, J Darpolor, M Cunetta, M Lima, **G Miller**, N Espat, and R Junghans STAT3 inhibition induces Bax dependent apoptosis in liver tumor myeloid derived suppressor cells. *Oncogene*. 2019; 38(4):533-548.

81. J Grunhut, W Wang, B Aykut, I Gakhal, A Torres-Hernandez, **G Miller**. Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe? *EMJ Hepatology* 2018; 6(1): 100–109.

82. BA Peters, JA Shapiro, TR Church, **G Miller**, C Trinh-Shevrin, E Yuen, C Friedlander, RB Hayes, J Ahn. A taxonomic signature of obesity in a large study of American adults. *Scientific Reports* 2018; 8(1):9749.

83. C Fedele, H Ran, W Wei, B Diskin, J Jen, M Geer, K Araki, U Ozerdem, DM Simeone, **G Miller**, B Neel, KH Tang. SHP2 Inhibition Prevents Adaptive Resistance to MEK inhibitors in Multiple Cancer Models. *Cancer Discovery*. 2018; 8(10):1237-1249.

84. W Wang, JM Marinis, AM Beal, S Savadkar, Y Wu, M Khan, PS Taunk, J Wu, N Wu, A Ahsan, E Kurz, T Chen, I Yaboh, M Khan, F Li, J Gutierrez, B Diskin, M Hundeyin, M Reilly, JD Lich, PA Harris, MK Mahajan, JH Thorpe, P Nassau, JE Mosley, J Leinwand, JA Kochen Rossi, A Mishra, B Aykut, M Glacken, A Ochi, N Verma, JI Kim, V

Vasudevaraja, D Adeegbe, C Almonte, E Bagdatlioglu, DJ Cohen, KK Wong, J Bertin, **G Miller**. RIP1 Kinase Drives Macrophage Mediated Adaptive Immune Tolerance in Pancreatic Cancer. *Cancer Cell*. 2018; 34(5):757-774.

85. D Lin, BA Peters, C Friedlander, HJ Freiman, JJ Goedert, R Sinha, **G Miller**, MA Bernstein, RB Hayes, J Ahn. Association of dietary fibre intake and gut microbiota in adults. *Br J Nutr*. 2018;120(9):1014-1022.

86. Torres-Hernandez A, Wang W, Nikiforov Y, Tejada K, Torres L, Kalabin A, Wu Y, Haq MIU, Khan MY, Zhao Z, Su W, Camargo J, Hundeyin M, Diskin B, Adam S, Rossi JAK, Kurz E, Aykut B, Shadaloey SAA, Leinwand J, **Miller G**. Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis. *Oncogene*. 2019; 38(23):4512-4526.

87. Sethi V, Vitiello GA, Saxena D, **Miller G**, Dudeja V. The role of the microbiome in immunologic development and its implication for pancreatic cancer immunotherapy. *Gastroenterology*. 2019; 156(7):2097-2115.

88. X Li, J Stern, G Miller, D Saxena. Virome and bacteriome: Two sides of the same coin. *Current Opinion in Virology*. 2019; 37:37-43.

89. RM Barilla, B Diskin, R Caso, KB Lee, N Mohan, C Buttar, S Adam, Z Sekendiz, J Wang, RD Salas, MF Cassini, J Karlen, B Sundberg, H Akbar, D Levchenko, I Gakhal, J Gutierrez, W Wang, M Hundeyin, A Torres-Hernandez, J Leinwand, Kurz, JA Kochen Rossi, A Mishra, M Liria, G Sanchez, J Panta, P Loke, B Aykut, **G Miller**. Specialized dendritic cells induce tumor-promoting IL-10^{+}IL-17^{+} FoxP3^{neg} regulatory $CD4^{+}$ T cells in pancreatic carcinoma. *Nature Communications*. 2019; 10(1):1424.

90. M Hundeyin, E Kurz, A Mishra, JA Kochen Rossi, AM Liudahl, H Mehrotra, M Kim, LE Torres, A Ogunsankin, KM Islam, I Dolgalev, S Savadkar, W Wang, B Aykut, J Leinwand, B Diskin, S Adam, M Israr, M Gelas, J Lish, K Chin, MS Farooq, J Wu, S Shah, D Adeegbe, S Pushalkar, V Vasudevaraja, D Saxena, KK Wong, LM Coussens, **G Miller**. Innate αβ T cells mediate anti-tumor immunity by orchestrating immunogenic macrophage programming. *Cancer Discovery*. 2019; 9(9):1288-1305.

91. PA Harris, JM Marinis, JD Lich, SB Berger, A Chirala, JA Cox, PM Eidam, JN Finger, PJ Gough, JU Jeong, J Kang, V Kasparcova, LK Leister, MK Mahajan, **G Miller**, R Nagilla, MT Ouellette, MA Reilly, AR Rendina, EJ Rivera, HH Sun, JH Thorpe, RD Totoritis, W Wang, D Wu, D Zhang, J Bertin, RW Marquis. Identification of a RIP1 kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer. *ACS Med Chem Lett*. 2019; 10(6):857-862.

92. BD Medina, **G Miller**. Rethinking T Cells in Pancreas Cancer. *Clinical Cancer Research*. 2019; 25(13): 3747-3749.

93. JC Leinwand, **G Miller**. Microbes as biomarkers and targets in pancreatic cancer. *Nature Reviews Clinical Oncology*. 2019; 16(11):665-666.

94. A Torres-Hernandez, W Wang, Y Nikiforov, K Tejada, L Torres, A Kalabin, S Adam, J Wu, L Lu, R Chen, A Lemmer, J Camargo, M Hundeyin, B Diskin, B Aykut, E Kurz, JA Kochen Rossi, M Khan, M Liria, G Sanchez, N Wu, W Su, S Adams, M Israr Ul Haq, MS Farooq, V Vasudevaraja, J Leinwand, **G Mille**r. γδ T cells promote steatohepatitis by orchestrating innate and adaptive immune programming. *Hepatology*. 2019; 71(2):477-494.

95. GA Vitiello, **G Miller**. Targeting the interleukin-17 immune axis for cancer immunotherapy. *Trends in Cancer*. 2019; 5(11):670-676.

96. B Aykut, S Pushalkar, R Chen, Q Li, R Abengozar, JI Kim, SAA Shadaloey, D Wu, P Preiss, N Verma, Y Guo, A Saxena, B Diskin, W Wang, J Leinwand, E Kurz, JA Kochen Rossi, M Hundeyin, C Zambrinis, X Li, D Saxena, **G Miller**. The fungal mycobiome promotes pancreatic oncogenesis via MBL activation. *Nature*. 2019; 574(7777):264-267.

97. AR Shakri, TJ Zhong, W Ma, C Coker, S Kim, S Calluori, H Scholze, M Szabolcs, T Caffrey, PM Grandgenett, MA Hollingsworth, K Tanji, MD Kluger, **G Miller**, AK Biswas and S Acharyya. Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia *Cancers* 2019;12(1):3.

98. GA Vitiello, **G Miller**. Targeting the interleukin-17 immune axis for cancer immunotherapy. *Journal of Experimental Medicine*. 2020; 217(1).

99. F Li, Q Huang, TA Luster, H Hu, H Zhang, WL Ng, A Khodadadi-Jamayran, W Wang, T Chen, J Deng, M Ranieri, Z Fang, V Pyon, CM Dowling, E Bagdatlioglu, C Almonte, K Labbe, H Silver, AR Rabin, K Jani, A Tsirigos, T Papagiannakopoulos, PS Hammerman, V Velcheti, GJ Freeman, J Qi, **G Miller**, KK Wong. In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma. *Cancer Discovery*. 2020: 10(2):270-287.

100. H Zhang, CL Christensen, R Dries, J Deng, B Diskin, F Li, Y Pan, X Zhang, Y Yin, E Papadopoulos, V Pyon, C Thakurdin, N Kwiatkowski, MG Oser, K Jani, AR Rabin, DM Castro, T Chen, H Silver, Q Huang, M Bulatovic, CM Dowling, B Sundberg, A Leggett, M Ranieri, H Han, S Li, A Yang, K Labbe, C Almonte, VO Sviderskiy, M Quinn, J Donaghue, ES Wang, T Zhang, Z He, V Velcheti, PS Hammerman, GJ Freeman, R Bonneau, WG Kaelin, K Sutherland, GC Yuan, E Rothenberg, **G Miller**, NS Gray, and KK Wong. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-Tumor Immunity in Small Cell Lung Cancer. *Cancer Cell*. 2020; 37(1):37-54.

101. B Aykut, R Chen, **G Miller**. Regulatory T Cells Keep Pancreatic Cancer at Bay. *Cancer Discovery*. 2020; 10(3):345-347

102. AM Seifert, C Reiche, M Heiduk, A Tannert, AC Meinecke, S Baiert, J von Renesse, C Kahlert, M Distler, T Welsch, C Reissfelder, DE Aust, **G Miller**, J Weitz, L Seifert. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. *Oncogene*. 2020; 39(15):3102-3113.

103. A Filipovic, **G Miller**, J Bolen. Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. *Front Cell Dev Biol*. 2020 Mar 17;8:155. doi:

10.3389/fcell.2020.00155

104. L Moro, D Simoneschi, E Kurz, AA Arbini, S Jang, N Guaragnella, S Giannattasio, W Wang, A Dang, E Hernandez, P Kapur, A Mishra, A Tsirigos, JT Hsieh, **G Miller**, M Pagano. Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. *Nature Cell Biology*. 2020, 22(9):1130-1142.

105. L Boytard,; Hadi, Tarik; Silvestro, Michele; Qu, Hengdong; Kumpfbeck, Andrew; Sleiman, Rayan; Fils, Kissinger Hyppolite; Alebrahim, Dornazsadat; Boccalatte, Francesco; Kugler, Matthias; Corsica, Annanina; Gelb, Bruce E; Jacobowitz, Glenn; **G Miller**, Bellini, Chiara; Oakes, Jessica; Silvestre, Jean-Sebastien; Zangi, Lior; Ramkhelawon, Bhama. 'Lung-derived HMGB1 is detrimental for vascular remodeling of metabolically imbalanced arterial macrophages. *Nature Communications*. 2020 11(1):4311.

106. B Diskin, S Adam, MF Cassini, G Sanchez, M Liria, B Aykut, C Buttar, E Li, B Sundberg, RD Salas, R Chen, J Wang, M Kim, MS Farooq, S Nguy, C Fedele, KH Tang, T Chen, W Wang, M Hundeyin, JA Kochen Rossi, E Kurz, MI Ul Haq, J Karlen, E Kruger, Z Sekendiz, D Wu, SAA Shadaloey, G Baptiste, G Werba[1], S Selvaraj, C Loomis, KK Wong, J Leinwand, **G Miller**. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. *Nature Immunology*. 2020; 21(4):442-454.

107. F Li, WL Ng, TA Luster, H Hu, VO Sviderskiy, CM Dowling, KER P Hollinshead, Zouitine, H Zhang, Q Huang, M Ranieri, W Wang, Z Fang, T Chen, J Deng, K Zhao, HC So, A Khodadadi-Jamayran, M Xu, A Karatza, V Pyon, S Li, Y Pan, K Labbe, C Almonte, JT Poirier, **G Miller**, R Possemato, J Qi, KK Wong. Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer. *Cancer Research*. 2020; 80(17):3556-3567.

108. J. Leinwand, **G Miller**. Regulation and Modulation of Anti-Tumor Immunity in Pancreatic Cancer. *Nature Immunology*. 2020; (10):1152-1159.

109. B Aykut, R Chen, JI Kim, D Wu, SAA Shadaloey, R Abengozar, P Preiss, A Saxena, S Pushalkar, J Leinwand, B Diskin, W Wang, G Werba, M Berman, SKB Lee, A Khodadadi-Jamayran, D Saxena, WA Coetzee, **G Miller**. Targeting Piezo1 unleashes innate immunity against cancer and infectious disease. *Science Immunology*. 2020;5(50):eabb5168. doi: 10.1126/sciimmunol.abb5168

110. J Wu, EC Atkinson, K Du, S Nguy, AC Pavlick, JD Goldberg, D Becker, E Shum, SY Lee, **G Miller**, J Chuy, L Leichman. A phase I study of immune checkpoint inhibition (anti-CTLA4 and anti-PD-L1) in combination with radiation therapy in patients with locally advanced unresectable pancreatic cancer. *Clinical Gastroenterology Journal*. 2020; DOI: 10.37421/cgj.2020.5.101

111. C Fedele, S Li, KW Teng, CJR Foster, D Peng, H Ran, P Mita, MJ Geer, T Hattori, A Koide, Y Wang, KH Tang, J Leinwand, W Wang, B Diskin, J Deng, T chen, I Dolgalev, U Ozerdem, **G Miller**, S Koide, KK Wong, BG Neel. SHP2 inhibition diminishes

KRASG12C cycling and promotes tumor microenvironment remodeling. *Journal of Experimental Medicine*. 2021 Jan 4;218(1):e20201414. doi: 10.1084/jem.20201414.

112. MO Miller, PC Kashyap, SL Becker, RM Thomas, RA Hodin, **G Miller**, M Hundeyin, S Pushalkar, D Cohen, D Saxena, BD Shogan, GJ Morris-Stiff. SSAT State-of-the-Art Conference: Advancements in the Microbiome. *Journal of Gastrointestinal Surgery*. 2021; 25(7):1885-1895.

113. M Elaksandrany, R Patel, M Patel, **G Miller**, D Saxena, A Saxena. Fungi, host immune response and tumorigenesis. *American Journal of Physiology-Gastrointestinal and Liver Physiology* 2021. 321(2):G213-G222.

114. JC Leinwand, B Paul, R Chen, MA Sierra, MM Paluru, S Nanduri, CG Alcantara, SAA Shadaloey, F Yang, SA Adam, Q Li, M Bandel, I Gakhal, L Appiah, Y Guo,M Vardahn, Z Flaminio, ER Grodman, A Mermelstein, W Wang, B Diskin, B Aykut, M Kahn, G Werba, G Baptiste, S Pushalkar, F Xu, JA Kochen Rossi, E Kurz, M McKinstry, Z Kluger, JJ park, B heishe, K Dancel-Manning, FX Liang, JS park, S Naik, A Saxena, X Lin, ND Theise, D Saxena, **G Miller**. Intrahepatic microbes govern liver immunity by programming NKT cells. *Journal of Clinical Investigation*, 2022; 132(8):e151725.

115. B Diskin, S Adam, G Sanchez Soto, M Liria, B Aykut, B Sundberg, E Li, J Leinwand, R Chen, M Kim, RD Salas, MF Cassini, W Wang, MS Farooq, SAA Shadaloey, G Werba, F Amreek, F Yang, C Hirsch, J Gilinski, A Panjwani, Y Weitzner, D Cohen, **G Miller**. $BTLA^{+}CD200^{+}$ B cells Dictate the Divergent Immune Landscape and Immunotherapeutic Resistance in Metastatic vs Primary Pancreatic Cancer. *Oncogene* 2022, 41(38):4349-4360.

116. Kurz E, Hirsch CA, Dalton T, Shadaloey SA, Khodadadi-Jamayran A, **Miller G**, Pareek S, Rajaei H, Mohindroo C, Baydogan S, Ngo-Huang A, Parker N, Katz MHG, Petzel M, Vucic E, McAllister F, Schadler K, Winograd R, Bar-Sagi D. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer. *Cancer Cell*. 2022; 40(7):720-737.

117. B Diskin, S Schwartz, **G Miller**. The critical immune basis for differential responses to immunotherapy in primary versus metastatic pancreatic cancer. *Oncotarget* 2023; 14:364-365. doi: 10.18632/oncotarget.28373.

118. SC Thomas, **G Miller**, X Li, D Saxena. Getting off Tract: contributions of intra-organ microbiota to cancer in extra-intestinal organs. *Gut* 2023; 73(1):175-185.

119. F Xu, D Saxena, S Pushalkar, **G Miller**. Revisiting the Mycobiome of the Pancreas and its Association with Pancreatic Cancer. *Nature* 2023; 620(7972):E1–E6. doi: 10.1038/s41586-023-06292-1.

120. J Stebbing**, G Miller**. Ten years of Oncogene editorialship: A decade of transformation. *Oncogene* 2025; 44(50):4833-4834.

Book Chapters

1. **G Miller**, R Berman. Gastric MALT Lymphoma. In: *Advanced Therapy in Surgical Oncology*, 2008, RA Pollock, editor

2. **G Miller**, WR Jarnagin. Cancer of the Biliary Tract and Gallbladder. In: *Textbook of Surgical Oncology*, 2008, Graeme J. Poston, editor

3. **G Miller**. Molecular pathogenesis of biliary tract cancer. In: *Blumgart's Surgery of the Liver and Biliary Tree*, 2012, William R Jarnagin, editor
4. **J Maggi, G Miller**. Cytokines in liver, biliary, and pancreatic disease. In: *Blumgart's Surgery of the Liver and Biliary Tree*, 2012, William R Jarnagin, editor

Invited Lectures

2022

Weizmann Institute: From Basic Cancer Research to Innovative Therapies (Rehovot, Israel): *The Hepatic Microbiome Governs Liver Immunity*

Yale-New Haven Health Waterbury Hospital (Waterbury, CT): Surgery Grand Rounds: *Investigational immunotherapy approaches to pancreatic cancer*

2021

Surgery-Biology Club: *Intrahepatic microbes govern liver immunity by programming NKT cells*

2020

New York Academy of Sciences (New York, NY): *Systemic effects of metastases in pancreatic cancer in humans and mouse models*

Infectious Disease Week (Zoom Meeting): *Role of fungi in pancreatic cancer progression*

2019

Memorial Sloan Kettering Cancer Center Department of Sugary Grand Rounds (New York, NY): *The microbiome and immunity in the liver*

Memorial Sloan Kettering Cancer Center Department of Sugary Research Seminar (New York, NY): *Corruption of tumor immunity by the reverse PDL1←PD1 axis*

Georgetown University Ruesch Symposium (Washington, DC): *New approaches to pancreatic cancer immunotherapy: from bench to bedside*

Henry Ford Pancreas Symposium (Detroit, MI): *Divergent immune landscape and immunotherapeutic response in metastatic vs primary pancreatic cancer*

University of Pennsylvania David Ginsburg Lectureship (Philadelphia, PA): *Microbial influences on pancreatic oncogenesis*

University of Louisville Brown Cancer Center Special Seminar (Louisville, KY): *Novel approaches to pancreatic cancer immunotherapy*

AACR Pancreatic Cancer: Advances in Science and Clinical Care. Opening Keynote Address (Boston, MA): *Targeting innate immunity in pancreatic cancer*

Digestive Disease Week Special Seminar (San Diego, CA): *Targeting the microbiome in pancreatic cancer*

University of Pittsburg Richard L Simmons Lecture in Surgical Science (Pittsburgh, PA): *New approaches to pancreatic cancer immunotherapy*

University of Pittsburg Hillman Cancer Center Special Seminar (Pittsburgh, PA): *Targeting the microbiome in pancreatic cancer*

University of Pennsylvania Kaufman Memorial Lectureship (Philadelphia, PA): *New approaches to pancreatic cancer immunotherapy*

University of Miami Sylvester Cancer Center, Keynote Speaker (Miami, FL): *Translating basic discoveries in pancreatic cancer to phase I clinical trials*

University of Michigan Cancer Biology Program Seminar Series (Ann Arbor, MI): *New approaches to pancreatic cancer immunotherapy*

2018

Pfizer Emerging Science Day Workshop on Tissue Resident Immunity (Cambridge, MA): *New approaches to pancreatic cancer immunotherapy*

Memorial Sloan Kettering Cancer Center, Rubenstein Center for Pancreas Cancer Seminar (New York, NY): *Is pancreatic cancer and infectious disease?*

University of Alabama Birmingham, Keynote Speaker at 6th Annual Metabolomics Workshop: *Microbial programming of the tumor microenvironment*

Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Seminar (New York, NY): *New approaches to pancreatic cancer immunotherapy*

Pancreatic Cancer Action Network, Keynote Speaker (San Diego, CA): *Role of the microbiome in pancreatic oncogenesis*

American Pancreatic Association – Hirshberg Opening Symposium (Miami, FL): *Is pancreatic cancer and infectious disease?*

National Cancer Research Institute UK (Glasgow, Scotland): *Pancreatic cancer immunotherapy from bench to bedside*

2017

American Pancreatic Association Annual Meeting Keynote Address (San Diego, CA): *Targeting RIP1 Kinase in pancreatic carcinoma*

Oregon Health and Science University, Knight Cancer Center Seminar (Portland, OR): *The gut microbiome promotes pancreatic oncogenesis by induction of innate and adaptive immune suppression*

NIH, National Institute on Alcohol Abuse and Alcoholism (NIAAA; Bethesda, MD): *γδ T cells regulate liver and pancreatic disease*

Memorial Sloan Kettering Cancer Center Department of Surgery Research Conference (New York, NY): *Dectin-1 – Galectin-9 axis promotes macrophage mediated adaptive immune suppression in pancreatic carcinoma*

Cold Spring Harbor Laboratories Banbury Conference (Cold Spring Harbor, NY): *Immunotherapy for pancreatic cancer*

2016

New York Tumor Microenvironment Symposium (Mount Sinai Hospital, NY): *Dectin-1 promotes macrophage mediated adaptive immune suppression in pancreatic carcinoma*

Pancreatic Cancer Action Network (San Diego, CA): *Inflammatory cell death and pancreatic oncogenesis*

Columbia University Medical Center Medical Oncology Grand Rounds (New York, NY): *Pancreas cancer immunotherapy: from bench to bedside*

University of North Carolina Cancer Center Seminar (Chapel Hill, NC): *Pancreas cancer immunotherapy: from bench to bedside*

Yale University School of Medicine Dept. of Pharmacology Seminar (New Haven, CT): *γδ T cell induction of adaptive immune suppression in pancreatic carcinoma*

Thomas Jefferson University Medical College Cancer Center Seminar (Philadelphia, PA): *Pancreas cancer immunotherapy from bench to bedside*

2015

Cold Spring Harbor Laboratories Banbury Conference (Cold Spring Harbor, NY): *Innate immune signaling in pancreatic carcinoma*

Whitmarsh Lecture, Roger Williams Medical Center (Providence RI): *Modern management of cholangiocarcinoma*

University of Minnesota Surgical Grand Rounds (Minneapolis, MN): *Radiation therapy induces tumor-promoting immune-suppression in pancreatic carcinoma*

University of Minnesota Basic Science Grand Rounds (Minneapolis, MN): *γδT cells support pancreatic oncogenesis by inducing αβT cell exhaustion*

2014

New York Academy of Sciences Symposium on 'Targeting Key Vulnerabilities in Pancreatic Cancer' (New York, NY): *Effect of SBRT and cell death on pancreatic oncogenesis*

AACR Special Conference on Pancreatic Cancer (New Orleans, LA): *Innate immune signaling in the pancreatic tumor microenvironment*

New York Tumor Microenvironment Symposium (Columbia University, NY): *Innate immune signaling in the pancreatic tumor microenvironment*

Memorial Sloan Kettering Cancer Center Department of Surgery Research Conference (New York, NY): *TLR signaling in the pancreatic tumor microenvironment*

Start-up companies founded & Pharma Partnerships

- 2017, Co-Founded NYBO Therapeutics (now Puretech Health)
- 2017, Partnered with GSK to bring RIP1 inhibitor to clinical trial
- 2019, Partnered with Pfizer to develop PIEZO1 antagonisits for cancer therapy
- 2020, Partnered with Pfizer to perform CRISPR screen in pancreatic cancer to discover novel immunotherapies to synergize with αPD1

New Therapeutics Developed Directly from my Research

- **LYT200** (αh-Galectin-9 mAb [Collaboration with Puretech])
- **LYT210** (αh-Gamma Delta T cell mAb [Collaboration with Puretech])
- **GSK3145095** (selective RIP1 inhibitor [Collaboration with GSK])
- **Pizeo1 inhibitor** (Collaboration with Pfizer)

Phase I & II Clinical Trials Developed Directly from Lab Work

- **NCT03681951** *First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors* (Phase I clinical trial in advanced PDA targeting RIP1)
- **NCT03599362** *Study of Nivolumab, Cabrializumab, and Stereotactic Body Radiotherapy for locally Advanced Unresectable Pancreatic Cancer* (Phase II clinical trial in locally advanced PDA patients Utilizing SBRT in combination with targeting MCSF signaling)
- **NCT04666688** *LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors* (Phase I clinical trial targeting Galectin-9 in solid organ tumors)
- **NCT05462496** *Modulation of the Gut Microbiome with Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer* (Phase I clinical trial targeting the microbiome in combination with immunotherapy)
- **NCT05483075** *Feasibility of Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer* (Phase I clinical trial evaluating effects of aerobic exercise on immune response in pancreatic cancer)
- **NCT05829226** A *Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)e* (Phase I clinical trial targeting Galectin-9 in acute myeloid leukemia or myelodysplastic syndrome)

Founded Entities (Start-up Companies)

- **NYBO Therapeutics (now Gallop Oncology)** (Scientific Founder; Cancer immunology start-up founded in 2017, Merged with Puretech Heath in 2020, 2 new cancer therapies, 2 active clinical trials, ~0.5 billion dollars market capitalization)

- **Zephyr AI** (Founding Scientific Advisor; Healthcare technology company committed to reshaping approaches to drug discovery by leveraging the power of artificial intelligence and machine learning, Raised ~100 million dollars).

PI on Clinical Trials

- **NCT04340141** Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.

Patents Filed

OIL ID	Country	Title	Application No.	FIling Date	Patent No.	Issue Date	Status
MIL02-05CA	Canada	Treating Solid Tumor by Targeting Dectin-1 Signaling	3032305	31-Jul-17			Pending
MIL02-05EP	Europe	Treating Solid Tumor by Targeting Dectin-1 Signaling	17835413	31-Jul-17			Pending
MIL02-05PCT	PCT	Treating Solid Tumor by Targeting Dectin-1 Signaling	PCT/US17/44680	31-Jul-17			Abandoned
MIL02-05US	United States	Treating Solid Tumor by Targeting Dectin-1 Signaling	15/664,720	31-Jul-17			Pending
MIL02-08PRO	United States	ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF	62/578,111	27-Oct-17			Abandoned
MIL02-09PRO	United States	Antibodies Specific to Delta 1 Chain of T Cell Receptor	62/620,813	23-Jan-18			Pending
MIL02-06PCT	PCT	METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING PANCREATIC CANCERS	PCT/US18/17052	6-Feb-18			Abandoned
MIL02-08PRO2	United States	ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF	62/665,175	1-May-18			Abandoned
MIL02-11PRO	United States	TARGETING PIEZO1 FOR TREATMENT OF CANCER AND INFECTIOUS DISEASES	62/713,344	1-Aug-18			Abandoned
MIL02-08PRO3	United States	Anti-Galectin-9 Antibodies and Uses Thereof	62/736,317	25-Sep-18			Pending
MIL02-09PRO2	United States	Antibodies Specific to Delta 1 Chain of T Cell Receptor	62/736,321	25-Sep-18			Pending
MIL02-08PCT	PCT	ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF	PCT/US18/58028	29-Oct-18			Pending
MIL02-08US	United States	ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF	16/173,970	29-Oct-18	10,344,091	9-Jul-19	Issued
MIL02-09PRO3	United States	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR	62/779,915	14-Dec-18			Pending
MIL02-09PCT	PCT	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR	PCT/US2019/014840	23-Jan-19			Pending
MIL02-09PRO4	United States	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR	62/796,061	23-Jan-19			Pending
MIL02-09US	United States	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR	16/255,769	23-Jan-19			Pending
MIL02-08PRO4	United States	Anti-Galectin-9 Antibodies and Uses Thereof	62/823,458	25-Mar-19			Pending
MIL02-09PRO5	United States	Antibodies Specific to Delta 1 Chain of T Cell Receptor	62/823,353	25-Mar-19			Pending
MIL02-08PRO5	United States	Anti-Galectin-9 Antibodies And Uses Thereof	62/841,730	1-May-19			Pending
MIL02-08PRO6	United States	Anti-Galectin-9 Antibodies And Uses Thereof	62/841,732	1-May-19			Pending

OIL ID	Country	Title	Application No.	FIling Date	Patent No.	Issue Date	Status
MIL02-09PRO7	United States	Antibodies Specific To Delta 1 Chain of T Cell Receptor And Methods of Using The Same	62/857,129	4-Jun-19			Pending
MIL02-09PRO8	United States	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR	62/874,313	15-Jul-19			Pending
MIL02-08PRO7	United States	Anti-Galectin-9 Antibodies And Uses Thereof	62/881,894	1-Aug-19			Pending
MIL02-11PCT	PCT	Targeting Piezo1 For Treatment of Cancer And Infectious Diseases	PCT/US2019/44703	1-Aug-19			Pending
MIL02-09PRO9	United States	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR	62/896,235	5-Sep-19			Pending
MIL02-08CON2	United States	Anti-Galectin-9 Antibodies And Uses Thereof	16/576,719	19-Sep-19			Pending
MIL02-12PRO	United States	METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING PANCREATIC CANCERS	62/909,037	1-Oct-19			Pending
MIL02-06US	United States	METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING PANCREATIC CANCERS	16/484,080				Pending